[Doubling complete histological response in sarcomas with radiation therapy using nanoparticles (Hafnium oxide, NBTXR3), a phase III trial]

Bull Cancer. 2019 Dec;106(12):1070-1072. doi: 10.1016/j.bulcan.2019.10.002. Epub 2019 Nov 21.

[Article in French]

Authors

Nazim Khalladi¹, Juliette Thariat²

Affiliations

¹ Centre François-Baclesse/ARCHADE, Department of Radiation, Oncology, 3, avenue Général-Harris, 14000 Caen, France.
² Centre François-Baclesse/ARCHADE, Department of Radiation, Oncology, 3, avenue Général-Harris, 14000 Caen, France; Normandie université, UNICAEN, ENSICAEN, CNRS/IN2P3, LPC Caen, 14000 Caen, France. Electronic address: jthariat@gmail.com.

PMID: 31761268
DOI: 10.1016/j.bulcan.2019.10.002

No abstract available

Publication types

News

MeSH terms

Clinical Trials, Phase I as Topic
Clinical Trials, Phase III as Topic
Dose Fractionation, Radiation
Hafnium / administration & dosage*
Hafnium / adverse effects
Humans
Multicenter Studies as Topic
Nanoparticles / administration & dosage*
Nanoparticles / adverse effects
Organs at Risk / radiation effects
Oxides / administration & dosage*
Oxides / adverse effects
Radiation-Sensitizing Agents / administration & dosage*
Radiation-Sensitizing Agents / adverse effects
Randomized Controlled Trials as Topic
Risk Assessment
Sarcoma / pathology
Sarcoma / radiotherapy*
Treatment Outcome

Substances

Oxides
Radiation-Sensitizing Agents
hafnium oxide
Hafnium